全文获取类型
收费全文 | 565篇 |
免费 | 30篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 20篇 |
妇产科学 | 4篇 |
基础医学 | 51篇 |
口腔科学 | 26篇 |
临床医学 | 60篇 |
内科学 | 99篇 |
皮肤病学 | 16篇 |
神经病学 | 28篇 |
特种医学 | 44篇 |
外科学 | 101篇 |
综合类 | 9篇 |
预防医学 | 23篇 |
眼科学 | 8篇 |
药学 | 44篇 |
中国医学 | 4篇 |
肿瘤学 | 60篇 |
出版年
2023年 | 3篇 |
2022年 | 12篇 |
2021年 | 17篇 |
2020年 | 9篇 |
2019年 | 9篇 |
2018年 | 24篇 |
2017年 | 10篇 |
2016年 | 16篇 |
2015年 | 11篇 |
2014年 | 16篇 |
2013年 | 41篇 |
2012年 | 41篇 |
2011年 | 25篇 |
2010年 | 34篇 |
2009年 | 14篇 |
2008年 | 33篇 |
2007年 | 36篇 |
2006年 | 31篇 |
2005年 | 25篇 |
2004年 | 19篇 |
2003年 | 23篇 |
2002年 | 25篇 |
2001年 | 5篇 |
2000年 | 5篇 |
1999年 | 3篇 |
1998年 | 4篇 |
1997年 | 2篇 |
1996年 | 3篇 |
1995年 | 4篇 |
1994年 | 3篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 3篇 |
1990年 | 10篇 |
1989年 | 7篇 |
1988年 | 4篇 |
1986年 | 3篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 4篇 |
1980年 | 4篇 |
1979年 | 5篇 |
1978年 | 4篇 |
1977年 | 4篇 |
1976年 | 7篇 |
1975年 | 2篇 |
1973年 | 4篇 |
1970年 | 3篇 |
1968年 | 4篇 |
1965年 | 3篇 |
排序方式: 共有599条查询结果,搜索用时 15 毫秒
61.
Krishan P. Singh Gang Li Fanny S. Mitrani-Gold Milena Kurtinecz Jeffrey Wetherington John F. Tomayko Linda M. Mundy 《Antimicrobial agents and chemotherapy》2013,57(11):5284-5290
Noninferiority trial design and analyses are commonly used to establish the effectiveness of a new antimicrobial drug for treatment of serious infections such as complicated urinary tract infection (cUTI). A systematic review and meta-analysis were conducted to estimate the treatment effects of three potential active comparator drugs for the design of a noninferiority trial. The systematic review identified no placebo trials of cUTI, four clinical trials of cUTI with uncomplicated urinary tract infection as a proxy for placebo, and nine trials with reports of treatment effect estimates for doripenem, levofloxacin, or imipenem-cilastatin. In the meta-analysis, the primary efficacy endpoint of interest was the microbiological eradication rate at the test-of-cure visit in the microbiological intent-to-treat population. The estimated eradication rates and corresponding 95% confidence intervals (CI) were 31.8% (26.5% to 37.2%) for placebo, 81% (77.7% to 84.2%) for doripenem, 79% (75.9% to 82.2%) for levofloxacin, and 80.5% (71.9% to 89.1%) for imipenem-cilastatin. The treatment effect estimates were 40.5% for doripenem, 38.7% for levofloxacin, 34.7% for imipenem-cilastatin, and 40.8% overall. These treatment effect estimates can be used to inform the design and analysis of future noninferiority trials in cUTI study populations. 相似文献
62.
Jeevan Lata Baldev Krishan Kapila Preeti Aggarwal 《International journal of oral and maxillofacial surgery》1996,25(6):455-456
Myiasis is a disease commonly seen in animals, especially sheep and cattle. The condition is rare in man. A patient with a neglected fractured mandible with superimposed myiasis is reported. 相似文献
63.
Rajesh K. Jain Shadi Lal Agnish Krishan Lal Hari L. Bhatnagar 《Macromolecular chemistry and physics.》1985,186(12):2501-2512
The reactivity of primary and secondary hydroxyl groups of cellulose towards chlorotri(p-tolyl)methane in pyridine was studied in the temperature range of 60 to 100°C. The rate of reaction with the primary hydroxyl groups was found to be 43 times faster than that with the secondary hydroxyl groups of cellulose. The kinetic data showed that the reactivity of chlorotri(p-tolyl)methane towards primary hydroxyl groups of cellulose is higher than that of chlorotriphenylmethane (trityl chloride). The energies of activation for the reaction of primary and secondary hydroxyl groups of cellulose with chlorotri(p-tolyl)methane were found to be 39,6 and 43,1 kJ · mol?1, respectively. The reaction was observed to be pseudo first order. 相似文献
64.
65.
66.
67.
68.
69.
Human gliomas are the most common primary central nervous system neoplasm, and they are a complex, heterogeneous, and difficult disease to treat. In the past two decades, advances in molecular biology have revolutionized our understanding of the mechanism by which these neoplasms are initiated and progress. While surgery, radiation therapy, and chemotherapy have roles to play in the treatment of patients with gliomas; these therapies are self-limited because of the intrinsic resistance of glioma cells to therapy, and the diffusely infiltrating nature of the lesions. It is now known that malignant gliomas arise from a number of well-characterized genetic alterations and activations of oncogenes and inactivation of tumor suppressor genes. These genetic alterations disrupt critical cell cycle, growth factor activation, apoptotic, cell motility, and invasion pathways that lead to phenotypic changes and neoplastic transformation. Research in each of these fields has uncovered potential therapeutic targets that look promising for disease control. Gliomas can now be modeled with fidelity and reproducibility using several transgenic and knockout strategies. Transgenic mouse models are facilitating the testing of various therapeutic strategies in vivo. Finally, the recognition of the putative brain tumor stem cell, the tumor initiating cell in brain cancer, provides an enticing target through which we could eliminate the source of the brain tumor with increased efficacy and less toxicity to normal tissues. In this review, we provide an up-to-date discussion of the many of key technologies and tools that are being used in molecular biology to advance our understanding of the biological behavior of human malignant gliomas. 相似文献
70.